Molecule
Trametinib dimethyl sulfoxide is a kinase inhibitor. It is available as tablets and powder for oral solution. MedsAcross supplies Trametinib dimethyl sulfoxide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
Source: US FDA prescribing information
Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. Trametinib inhibits cell growth of various BRAF V600 mutation-positive tumors in vitro and in vivo. Trametinib and dabrafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of trametinib and dabrafenib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumor cell lines in vitro and prolonged inhibition of tumor growth in BRAF V600 mutation-positive tumor xenografts compared with either drug alone.
Source: US FDA prescribing information
The recommended dosage of MEKINIST in adult patients is 2 mg orally once daily. The recommended dosage for MEKINIST in pediatric patients is based on body weight.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
New Primary Malignancies, Cutaneous and Non-Cutaneous: Can occur when MEKINIST is used with dabrafenib. Monitor patients for new malignancies prior to, or while on therapy, and following discontinuation of treatment. Hemorrhage: Major hemorrhagic events can occur. Monitor for signs and symptoms of bleeding. Colitis and Gastrointestinal Perforation: Colitis and gastrointestinal perforation can occur in patients receiving MEKINIST. Venous Thromboembolic Events: Deep vein thrombosis (DVT) and pulmonary embolism (PE) can occur in patients receiving MEKINIST. Cardiomyopathy: Assess left ventricular ejection fraction (LVEF) before treatment, after one month of treatment, then every 2 to 3 months thereafter. Ocular Toxicities: Perform ophthalmological evaluation for any visual disturbances. For Retinal Vein Occlusion (RVO), permanently discontinue MEKINIST.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: New Primary Malignancies Hemorrhage Colitis and Gastrointestinal Perforation Venous Thromboembolic Events Cardiomyopathy Ocular Toxicities Interstitial Lung Disease/Pneumonitis Serious Febrile Reactions Serious Skin Toxicities Hyperglycemia Hemophagocytic Lymphohistiocytosis There are additional adverse reactions associated with dabrafenib. Refer to the dabrafenib prescribing information for additional information. Most common adverse reactions (≥ 20%) for MEKINIST as a single agent include rash, diarrhea, and lymphedema. Most common adverse reactions (≥ 20%) for MEKINIST in combination with dabrafenib include: Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema.
Source: US FDA prescribing information
MEKINIST is indicated for use in combination with dabrafenib. Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). Store refrigerated at 2°C to 8°C (36°F to 46°F). Protect from moisture and light. Store in the original carton to protect from light and moisture. After reconstitution, store in the original bottle below 25°C (77°F) and do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Trametinib dimethyl sulfoxide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Mekinist 0.05 mg/mL powder for oral solutionOral Cold chain | Novartis Pharmaceuticals | US FDA | Available on request |
| Mekinist 0.5 mg tabletOral Cold chain | Novartis Pharmaceuticals | US FDA | Available on request |
| Mekinist 2 mg tabletOral Cold chain | Novartis Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 29 May 2013 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Trametinib dimethyl sulfoxide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Trametinib dimethyl sulfoxide, including Mekinist.
Yes. The US FDA first approved Trametinib dimethyl sulfoxide on 29 May 2013, according to Drugs@FDA.
At least one listed presentation of Trametinib dimethyl sulfoxide must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.